Antiplatelet therapy - choose aspirin!
Aspirin is the most widely studied antiplatelet drug. On the basis of >100 randomized trials in high-risk patients, aspirin is shown to reduce vascular death by ~15% and non-fatal vascular events by ~30%(1)
Ideal dosage - choose 100mg!
The indirect comparisons reported in the overview of Antithrombotic Trialists Collaboration
summarised 12 trials with a total of 6,776 high risk patients, confirmed that doses
between 75-150 mg daily reduced vascular events by 26-38%. Doses over 160 mg reduced
these odds by up to 22% according to another 53 trials (48,964 patients) while doses
less than 75 mg dropped to as low as 5% evidenced by 3 trials and 3,655 patients
Administration - choose "regular" Aspirin!
The oral bioavailability of regular aspirin tablets is ~40% to ~50% over a wide range of doses.
A considerably lower bioavailability has been reported for enteric-coated tablets and
for sustained-release, microencapsulated preparations.(3)
Enteric-coated formulations do not modify the risk of upper gastrointestinal
complications in the general
population of low-dose aspirin.(4)
Affordability - choose MYOPRIN!
Myoprin 100 mg Tablets are the most affordable low dose aspirin
available and are supplied in a convenient quality monthly pack
with with easy-to-tear foil packaging(5)